Pages that link to "Q37950588"
Jump to navigation
Jump to search
The following pages link to HSP90 inhibitors as therapy for multiple myeloma (Q37950588):
Displaying 12 items.
- Targeting Plasmodium falciparum Hsp90: Towards Reversing Antimalarial Resistance (Q26864290) (← links)
- Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms (Q27692033) (← links)
- Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma (Q28296718) (← links)
- Heat shock protein 90 inhibitors repress latent membrane protein 1 (LMP1) expression and proliferation of Epstein-Barr virus-positive natural killer cell lymphoma. (Q34713316) (← links)
- Heat shock factor 1 confers resistance to Hsp90 inhibitors through p62/SQSTM1 expression and promotion of autophagic flux (Q35057071) (← links)
- Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita (Q37055162) (← links)
- Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation (Q37644930) (← links)
- Emerging biological insights and novel treatment strategies in multiple myeloma (Q38037600) (← links)
- When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response (Q38503345) (← links)
- Heat shock protein 90 inhibitors repurposed against Entamoeba histolytica (Q40613223) (← links)
- Kinome expression profiling of human neuroblastoma tumors identifies potential drug targets for ultra high-risk patients (Q47715440) (← links)
- [Research on multiple myeloma cell apoptosis by inhibition of mTORC2 and chaperon pathways]. (Q52910208) (← links)